Fierce Pharma April 26, 2024
Angus Liu

Novartis has started cutting ties with Chinese contractors amid a potential threat from the BIOSECURE Act. Neurocrine Biosciences is considering moving a depression drug candidate licensed from Takeda into phase 3 testing. AstraZeneca and Daiichi Sankyo’s Enhertu is on the cusp of an important readout in HER2-low breast cancer. And more.

1. Novartis ‘actively’ reviewing relationships with Chinese contractors amid US biosecurity crackdown: CFO

As the BIOSECURE Act threatens to block certain biotech equipment and service providers from China, Novartis has begun cutting ties with Chinese contractors. The company will mitigate the impact from the proposed legislation “in a very reasonable time frame” so that “by the time this comes into effect, we will have no exposure from our planning,”...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Related Articles:
Asembia: Pharmacists Have a Role in Health Care System Sustainability
Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite FDA Challenge
Zenas adds $200M series C to reach a bucket of key readouts for its lead monoclonal antibody
Hype and Disruption: Post-Dagdigian Trends Talk Splits in Two
Milken Institute: How employers can change the paradigm for obesity care

Share This Article